Rituximab, Methotrexate, Carmustine, Etoposide, and Prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: a retrospective single-center study.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carmustine
/ therapeutic use
Central Nervous System
/ pathology
Central Nervous System Neoplasms
/ diagnosis
Etoposide
/ adverse effects
Female
Humans
Lymphoma, Non-Hodgkin
/ diagnosis
Methotrexate
/ therapeutic use
Neoplasm Recurrence, Local
/ pathology
Prednisone
/ adverse effects
Retrospective Studies
Rituximab
Lymphoma and Hodgkin disease
chemotherapeutic approaches
pharmacotherapeutics
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
pubmed:
12
11
2021
medline:
15
4
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Relapsed/refractory Primary Central Nervous System Lymphoma (R/R PCNSL) has a poor prognosis with no established preferred treatment. We report the efficacy and toxicity of a combination chemotherapy regimen: methotrexate, carmustine, etoposide, and prednisone with or without rituximab (RMBVP). This retrospective study included thirty patients who received a median of two 28-day cycles (0.5-5). The median age was 66 years (23-81); median KPS was 70 (30-90); 14 (46.7%) were women. Patients received a median of 2 prior lines of therapy and all received prior methotrexate. Of 29 evaluable patients, the overall response rate was 73.3% (
Identifiants
pubmed: 34758711
doi: 10.1080/10428194.2021.1998481
pmc: PMC9703641
mid: NIHMS1848310
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Etoposide
6PLQ3CP4P3
Carmustine
U68WG3173Y
Prednisone
VB0R961HZT
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
627-632Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Lancet. 2009 Oct 31;374(9700):1512-20
pubmed: 19767089
J Clin Oncol. 2005 Aug 1;23(22):5034-43
pubmed: 15955902
Neuro Oncol. 2018 Apr 9;20(5):687-694
pubmed: 29036697
Clin Cancer Res. 2004 Sep 1;10(17):5643-6
pubmed: 15355887
Lancet Oncol. 2019 Feb;20(2):216-228
pubmed: 30630772
Cancer. 2011 May 1;117(9):1917-27
pubmed: 21509769
J Neurooncol. 2014 Mar;117(1):161-5
pubmed: 24481997
Br J Cancer. 1999 Feb;79(3-4):530-4
pubmed: 10027325
J Neurooncol. 2006 Nov;80(2):159-65
pubmed: 16699873
Neuro Oncol. 2016 Sep;18(9):1297-303
pubmed: 26951382
J Clin Oncol. 2017 Jul 20;35(21):2410-2418
pubmed: 28640701